Current Clinical Trials
To advance knowledge, identify the most effective care and help future patients, the Edwards Comprehensive Cancer Center maintains an active clinical trials program and maintains a listing of the clinical trials that are currently available.
If you have questions about whether a clinical trial is an option for you, please contact Barbara Payne, RN, OCN, CCRP, Clinical Research Supervisor. For more information about Pediatric Clinical Trials, please contact Teresa Giles at 304.399.6653.
| Code | Description | Type |
|---|---|---|
| Metabolomic Signatures of Human Liver Function in Health and Disease. | Biomarker | |
| 2008P-000285 | Biomechanics of Metastatic Defects in Bones. | Supportive Care |
| A011202 | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy | Breast Cancer |
| A011401 | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer | Breast Cancer |
| A011502 | A Randomized Phase III double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial - an Alliance Trial. | Breast Cancer |
| A021502 | Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair | Gastrointestinal Cancer |
| A031501 | Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation | Genitourinary Cancer |
| A081105 | (component study of ALCHEMIST) Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). | Lung Cancer |
| A151216 | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). | Lung Cancer |
| A211601 | Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502 | Breast Cancer |
| A221602 | Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial | Supportive Care |
| ACSCO | Avastin plus Chemotherapy versus Avastin plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Platinum-Resistant or –Sensitive Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer. | Gynecologic Cancer |
| AFT-39 | Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial) | Supportive Care |
| BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. | Breast Cancer |
| E4512 | A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. | Lung Cancer |
| EA5142 | (component study of ALCHEMIST)A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. | Lung Cancer |
| EA6141 | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma. | Melanoma |
| EAY131 | Molecular Analysis for Therapy Choice (MATCH). | Precision Medicine |
| GY005 | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS). | Gynecologic Cancer |
| LungMAP | A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) | Lung Cancer |
| S1207 | Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. | Breast Cancer |
| S1416 | Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. | Breast Cancer |
| S1418 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant chemotherapy). | Breast Cancer |
| S1609 | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors. | Rare Tumors |
| S1613 | A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification | Gastrointestinal Cancer |
| S1616 | A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent. | Melanoma |
| S1900A | A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) | Lung Cancer |
| Tart Cherry Juice | Effects of Tart Cherry Juice in Non-Metastatic Breast Cancer Patients with Aromatase Inhibitor Induced Arthralgia. | Breast Cancer |
| Code | Description | Type |
|---|---|---|
| AAML1531 | Risk Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome. Temp. Closed |
Leukemia/Lymphoma |
| ANBL1232 | Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. *Patient must be enrolled on ANBL00B1 prior to enrollment. | Neuroblastoma |
